Net Loss per Share (Tables)

3 Months Ended

Mar. 31, 2024

Earnings Per Share [Abstract]

Schedule of Antidilutive Shares Excluded From Calculation of Diluted Net Loss Per Share

The following table presents the potentially dilutive shares that were excluded from the computation of diluted net loss per share of Common Stock attributable to Common Stock stockholders because their effect was anti-dilutive:

	Three Months Ended March 31,
	2024	2023
Shares issuable upon conversion of SPA Notes and settlement of make-whole provisions	93,243,053	1,299,801
Shares issuable upon conversion of Unsecured Convertible Notes	15,624,025	—
Shares issuable upon exercise of SPA Warrants	558,689	389,881
Other warrants	9,139,280	122,728
Stock-based compensation awards – Options	109,224	154,925
Stock-based compensation awards – RSUs	857,530	83,880
Public warrants	98,088	98,088
Private warrants	464	464
Total	119,630,353	2,149,767